Filing Scope and Business Context
The source text is an Aileron Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2018, filed March 29, 2019. The request metadata identifies Rein Therapeutics, Inc., but the filing itself identifies Aileron Therapeutics, Inc.; this discrepancy should be verified.
Aileron was a clinical-stage biopharmaceutical company developing stabilized cell-permeating alpha-helical peptides for oncology and other therapeutic areas. Its lead candidate, ALRN-6924, was designed to reactivate wild-type p53 by disrupting MDM2 and MDMX interactions with p53. The company had no approved products and no product-sales revenue.
Financial Performance and Liquidity
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $18.448 million | $14.239 million | +$4.209 million |
| General and administrative expense | $13.454 million | $8.769 million | +$4.685 million |
| Total operating expenses | $31.902 million | $23.008 million | +$8.894 million |
| Net loss | $31.547 million | $22.604 million | +$8.943 million loss |
| Operating cash flow | $(27.926) million | $(20.531) million | $(7.395) million |
| Cash, cash equivalents and investments at year-end | $20.695 million | $50.752 million | $(30.057) million |
The company reported a 2018 net loss per share of $2.14, compared with $3.04 in 2017. Total assets were $30.312 million and total liabilities were $10.712 million at December 31, 2018. The company had no conventional long-term debt disclosed, but reported a $5.342 million construction financing liability associated with its new facility.
Investing activities provided $24.688 million in 2018, primarily from net sales or maturities of investments, while $4.423 million was spent on property and equipment for the new facility. Financing activities provided $2.515 million, primarily from construction financing. The company reported an accumulated deficit of $168.493 million.
Management stated that year-end cash, cash equivalents and investments were expected to fund operations and capital requirements only into the third quarter of 2019. The audited financial statements included a substantial-doubt going-concern emphasis.
Material Changes Versus 2017
- Research and development expense increased 30%, driven by expanded combination research, higher clinical data-management and monitoring costs, and increased personnel-related spending. Manufacturing costs declined because sufficient ALRN-6924 supplies had been produced during 2017.
- General and administrative expense increased 53.4%. The increase included approximately $1.1 million related to a separation agreement with the former chief executive officer, including salary continuation and stock-option modifications.
- Operating cash burn increased from $20.531 million to $27.926 million.
- Investment balances declined materially as the company used cash to fund operations and facility expenditures.
- The company moved into a new approximately 18,768-square-foot Watertown, Massachusetts office and laboratory facility under an eight-year lease. The minimum rent commitment for the initial term was approximately $8.771 million.
- Clinical development priorities shifted away from PTCL, AML and MDS toward the ALRN-6924/palbociclib combination in MDM2-amplified solid tumors and a planned myelopreservation trial.
Pipeline, Outlook and Key Risks
- In November 2018, Aileron announced a collaboration with Pfizer to evaluate ALRN-6924 plus palbociclib. A Phase 2a trial began in January 2019, targeting up to 25 patients with MDM2-amplified tumors or MDM2/CDK4 co-amplified tumors and wild-type p53.
- Management expected interim combination-trial results in the second half of 2019 and planned to begin a Phase 1b/2 myelopreservation trial in small-cell lung cancer in September 2019.
- The company ceased enrollment and further development in PTCL, AML and MDS at that time because of limited resources, commercial assessments and increased competition. One AML/MDS patient died of treatment-related tumor lysis syndrome in a single-agent Phase 1 trial.
- In the Phase 1 all-comers trial, 30 of 63 evaluable patients demonstrated disease control, including two complete responses and two partial responses. These results were preliminary and from early-stage, non-randomized development.
- Aileron relied on third parties for clinical research, manufacturing, fill-and-finish, storage and distribution. The active pharmaceutical ingredient for ALRN-6924 was sourced from a single contract manufacturer without redundant supply arrangements.
- The company had no approved products, no product revenue, no committed external funding source and expected continuing operating losses. Additional equity, debt, collaboration or licensing financing was required and could dilute shareholders or require the company to relinquish rights.
- On March 28, 2019, the company entered into an agreement for an approximately $26 million private placement, before fees and expenses, involving common shares, pre-funded warrants and warrants. The filing stated that closing was expected April 2, 2019, but proceeds could not be treated as probable for going-concern purposes until received.
- Other significant risks included clinical-trial failure or delay, regulatory rejection, possible companion-diagnostic requirements, competition from MDM2 inhibitors and other oncology therapies, intellectual-property challenges, license-compliance obligations and reimbursement uncertainty.
Investor Verification Priorities
- Verify the issuer identity: the filing is for Aileron Therapeutics, Inc., not Rein Therapeutics, Inc.
- Confirm whether the approximately $26 million private placement closed and determine the resulting share and warrant dilution.
- Reconcile current cash and liquidity with the stated third-quarter 2019 runway and the going-concern disclosure.
- Review subsequent clinical results for the ALRN-6924/palbociclib trial and the planned myelopreservation program.
- Assess the implications of the treatment-related tumor lysis syndrome death and the decision to discontinue PTCL, AML and MDS development.
- Review the single-source API supply arrangement, license milestones and royalty obligations, including the historical dispute raised by Harvard regarding development milestones.
- Confirm the status of any required companion diagnostic and the regulatory pathway for ALRN-6924.